CTLA4 and neoplasm: Pfirschke, et al. reported that autochthonous tumors lacking T cell infiltrates could be sensitized to anti-tumor immunity when suitable ICD inducers, such as oxaliplatin and cyclophosphamide, were combined with anti-PD-1 and/or anti-CTLA-4.